Zydus Lifesciences Ltd Share Price Today

Actions	Ex-Date	Record-Date
DividendsFinal Dividend of 100% at ₹1/Share	24-Jul-2026	24-Jul-2026
DividendsFinal Dividend of 1100% at ₹11/Share	25-Jul-2025	25-Jul-2025

Mutual Fund Holder	Aug 26 Shares held	Sep 26 Shares held
Parag Parikh Flexi Cap Fund - Regular Plan - Growth	1.93 Cr	1.93 Cr no change
Kotak Flexi Cap Fund - Growth	1.04 Cr	1.04 Cr no change
HSBC Midcap Fund - Regular Plan - Growth	29.33 Lac	40.79 Lac (39.07%)
Bandhan Large & Mid Cap Fund - Regular Plan - Growth	20.19 Lac	29.58 Lac (46.46%)
ICICI Prudential Large Cap Fund - Growth	24.81 Lac	24.81 Lac no change

MNC RESEARCH

8 Oct • 10:28 AM · SEBI-Registered Analyst

PHARMA SECTOR SHOWING SUPER STRENGTH AMID WEAKER MARKETS

One interesting trend in the current market is the relative strength being displayed by Pharma stocks. During the COVID period, Pharma stocks had a completely different story. Despite many companies having strong fundamentals and robust businesses, the sector witnessed significant selling and several quality Pharma stocks were beaten down heavily once the initial COVID euphoria faded. Fast forward to today — the scenario looks very different. While the broader market is facing pressure, several Pharma stocks are holding their ground and continuing to show strong price action. Stocks like Divi’s Labs, Laurus Labs, Torrent Pharma, Zydus Lifesciences, Sun Pharma and Lupin are among the names showing encouraging strength. For me, the important takeaway is not simply that Pharma is rising — it is that Pharma is showing strength when the broader market is weak. That kind of relative strength often deserves attention. When the market becomes volatile, sectors that refuse to participate in the downside can potentially become the leaders when market sentiment improves. Pharma is definitely a sector I would keep on the radar for momentum and swing-trading opportunities.

Palak Jain

6 Oct • 5:22 PM · SEBI-Registered Analyst

Zydus Lifesciences just entered the US market with something

It has launched the first generic version of Adempas in the US, in partnership with MSN Laboratories. 💊 The drug is called Riociguat and is used for pulmonary hypertension, a serious condition affecting the lungs and heart.

ZYDUSLIFE

Why does “first generic” matter? Because Zydus and MSN are currently the first companies to launch this generic in the US across all five approved strengths. And here’s the number that caught my attention. The original Adempas generated around $850 million in global sales in 2025, according to Bayer’s annual report. Now, that does NOT mean Zydus will suddenly get $850 million of revenue. Generics face competition, pricing pressure and market-share battles. But being first to market can give a company an important early advantage before other generic players enter. For Zydus, this is another example of why its complex-generics pipeline matters. The stock-market question is simple: Can Zydus convert this first-mover advantage into meaningful US revenue and profitability? Because in pharma, getting approval is one milestone. Getting market share is the real game. 📊

Umang Bhutada

6 Oct • 4:27 PM · SEBI-Registered Analyst

Zydus launches first generic Adempas in the US

ZYDUSLIFE

Zydus Lifesciences Limited, in partnership with MSN Laboratories, has launched the first generic version of Adempas (riociguat tablets) in the US across all five strengths: 0.5 mg, 1 mg, 1.5 mg, 2 mg and 2.5 mg. The product has USFDA approval and is indicated for certain patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension. The product was developed and manufactured by MSN, while Zydus brings its established US commercial platform. Importantly, Bayer reported global Adempas sales of approximately US$850 million in 2025, although US sales of riociguat are not separately disclosed by IQVIA. Why this matters Being first to market can provide an important commercial window before additional generic competition arrives. But the addressable market should not be confused with Zydus's potential revenue. Pricing, market share, competition and the commercial economics of the partnership will determine the actual earnings contribution. What to monitor next US launch and prescription uptake. Pricing and future generic competition. Revenue contribution and margins. Zydus's share of the economics with MSN. Further complex-generic launches. My analytical view: This is a meaningful US product launch because Zydus and MSN are first to market. The key catalyst now shifts from regulatory approval to commercial execution and sustainable market share. SEBI RA Disclaimer: Umang Rajesh Bhutada is a SEBI-registered Research Analyst (INH000023001). This content is for educational and informational purposes only and is not investment advice. Securities investments are subject to market risks. Please consult a qualified financial professional before making investment decisions.

Shrikant Pandey

5 Oct • 9:08 PM · SEBI-Registered Analyst

ZYDUS LIFESCIENCES: LAUNCHES FIRST GENERIC

ZYDUS LIFESCIENCES: LAUNCHES FIRST GENERIC OF ADEMPAS IN THE U.S.

ZYDUSLIFE

• Zydus Lifesciences, in collaboration with MSN Laboratories, has launched the first generic version of Adempas® (Riociguat) in the U.S. market. • Riociguat tablets are available in 0.5 mg, 1 mg, 1.5 mg, 2 mg and 2.5 mg strengths and are FDA-approved as a generic equivalent of Adempas®. • The product was developed and manufactured by MSN Laboratories, while Zydus brings its established U.S. commercial platform to the partnership. • Riociguat is indicated for adults with pulmonary arterial hypertension (PAH) and certain forms of chronic thromboembolic pulmonary hypertension (CTEPH). • Global sales of branded Adempas were approximately EUR 745 million (around USD 850 million) in 2025, according to Bayer’s 2025 annual report. Impact: Positive — Being the first generic entrant gives Zydus an early-mover opportunity in a sizeable specialty-drug market and strengthens its complex-generics portfolio. However, the eventual financial benefit will depend on pricing, market penetration and competition.

Hruthik N

4 Oct • 11:40 PM · SEBI-Registered Analyst

Zydus Hits a 2-Year High on Chronic Push

ZYDUSLIFE

has been one of the standout stories in Indian pharma recently, with shares touching a two-year high on October 2, though a closer look at the numbers shows a more complicated picture than the headline price action suggests. 1)The rally has real momentum. The stock is up 33% over the past six months and has rebounded 47% from its 52-week low of ₹835.85 (touched March 2, 2026), making it the best-performing pharmaceutical stock over both the past month and three months. 2)The chronic therapy shift is the core growth driver. Zydus's chronic portfolio now contributes 54% of trailing 12-month revenue, up 360 basis points over the last four years, a genuine structural shift toward higher-margin, India-focused business rather than reliance on generics alone. 3)But there's a real disconnect in the numbers. While revenue grew 22% in the most recent quarter, net profit actually fell 36% over the same period, a significant gap that investors are clearly weighing against the strong top-line growth story. 4)New launches are offsetting a known headwind. The decline in sales from the generic version of cancer drug Revlimid has reportedly been offset by new niche product launches, according to PL Research, suggesting management has managed a difficult product transition reasonably well.

Shree Dhanraksha Securities

30 Sep • 7:00 AM · SEBI-Registered Analyst

Pharmaceuticals Sector - Zydus Lifesciences Limited

Zydus Lifesciences Ltd.

ZYDUSLIFE

recently reported that a USFDA inspection of its pharmacovigilance and post-marketing system at its USA office concluded with nil observations on September 26, 2026. Regulatory outcomes are particularly important for pharmaceutical companies because manufacturing compliance, product approvals, inspections and the regulatory pipeline can materially affect future revenue. Zydus also reached a fresh 52-week high during the September 25 trading session, illustrating how regulatory developments and market expectations can interact. The key learning point is that pharmaceutical-stock analysis requires investors to examine regulatory compliance, product approvals, US exposure, R&D pipeline, pricing pressure and patent risks, rather than simply comparing P/E ratios.

Zydus Lifesciences Ltd. Share Price

Overview

Market Data

Open Price

Prev. Close

Day Low

Day High

52 Week Low

52 Week High

Fundamentals

Quick Bite

Price To Earnings Ratio

Sector PE

PB Ratio

Sector PB

EPS

Dividend Yield

Today's Volume

5 Day Avg. Volume

PEG Ratio

Market Cap.

StockGro Trade views

Technical Analysis

Forecasts 🧭

Financials

Corporate Actions

Mutual Fund Ownership

About Zydus Lifesciences Ltd. 👋

Expert Opinions

News & Events

Frequently Asked Questions

What is the share price of Zydus Lifesciences Ltd.?

What is the market cap of Zydus Lifesciences Ltd.?

Should I buy Zydus Lifesciences Ltd. stock now?

What is the 52 week high and low of Zydus Lifesciences Ltd.?

Is the Zydus Lifesciences Ltd. stock good to buy?

Is Zydus Lifesciences Ltd. a good buy for the long term?

Is Zydus Lifesciences Ltd. overvalued or undervalued?

What is the PE and PB ratio of Zydus Lifesciences Ltd.?